imipramine has been researched along with Depressive Disorder, Major in 147 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Decreased PGD2 levels in major depressive disorder are associated with depression-like behaviors." | 5.46 | Decreased Prostaglandin D2 Levels in Major Depressive Disorder Are Associated with Depression-Like Behaviors. ( Chu, C; Shen, Y; Wei, H; Xu, Q; Zhu, W, 2017) |
| "There were no significant differences among the three visits in the mirtazapine, imipramine, or control groups in terms of pain, nausea, vomiting, or appetite loss." | 5.13 | Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. ( Akbiyik, DI; Alkis, N; Cankurtaran, ES; Ozalp, E; Soygur, H; Turhan, L, 2008) |
| "Subjects diagnosed with DSM-III-R chronic major depressive disorder or double depression (dysthymia with concurrent major depressive episode) were randomly assigned between February 1993 and December 1994 to 12 weeks of double-blind treatment with flexibly-dosed sertraline or imipramine, with crossover to the alternate drug in the absence of response." | 5.12 | Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status. ( Clary, CM; Harvey, AT; Kornstein, SG; Silkey, BS, 2007) |
| "This was a multisite study in which outpatients with chronic major depression (with or without concurrent dysthymia), who failed to respond to 12 weeks of double-blind treatment with either sertraline hydrochloride (n = 117) or imipramine hydrochloride (n = 51), were crossed over or switched to 12 additional weeks of double-blind treatment with the alternate medication." | 5.10 | Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. ( Fawcett, J; Gelenberg, AJ; Harrison, W; Hirschfeld, RM; Howland, RH; Keller, MB; Klein, DN; Kocsis, JH; Koran, LM; Kornstein, SG; LaVange, LM; Rush, AJ; Russell, JM; Schatzberg, AF; Thase, ME, 2002) |
| "After 12 weeks of acute phase treatment in a double-blind, randomized, parallel-group, multi-center trial of sertraline or imipramine, patients with chronic depression (> or = 2 years in major depression, or major depression superimposed on dysthymia) continued study drug for 16 weeks." | 5.09 | Sertraline versus imipramine to prevent relapse in chronic depression. ( DeBattista, C; Friedman, RA; Gelenberg, AJ; Hirschfeld, RM; Howland, RH; Keller, MB; Klein, D; Kocsis, JH; Koran, LM; Kornstein, SG; LaVange, LM; Rush, AJ; Schatzberg, AF; Thase, ME, 2001) |
| " In addition to non-difference between drug-types, outcomes were unrelated to reporting-year, trial-size or nominal duration, proportion of women participants, initial depression ratings, rating scales, subjects/arm, imipramine-equivalent mg/day drug dose, or dropout rate." | 4.95 | Direct comparison of tricyclic and serotonin-reuptake inhibitor antidepressants in randomized head-to-head trials in acute major depression: Systematic review and meta-analysis. ( Baldessarini, RJ; Undurraga, J, 2017) |
| "Compared with controls, [(3)H]AF-DX 384 binding was lower in BA 24 and BA 46 in bipolar disorders and major depressive disorders, while CHRM2 protein and oxotremorine-M stimulated [(35)S]GTPγS binding was only lower in BA 24." | 3.83 | Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants. ( Dean, B; Gibbons, AS; Jeon, WJ; Scarr, E, 2016) |
| " Subsequently, density of [(3)H]LY341495 binding was measured in BA24(anterior cingulate cortex), BA17(visual cortex) and BA46(dorsolateral prefrontal cortex) from subjects with MDD, Bipolar Disorder(BPD), Schizophrenia(SCZ), and controls, as well as rats treated with imipramine (20mg/kg), fluoxetine (10mg/kg), or vehicle." | 3.83 | Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia. ( Dean, B; Gibbons, A; Hopper, S; McOmish, CE; Pavey, G; Scarr, E; Udawela, M, 2016) |
| " In situ [3H]ketanserin binding and autoradiography was used to measure levels of HTR2A in Brodmann's area (BA) 46 and 24 from people with major depressive disorders (MDD, n = 16), bipolar disorders (BD, n = 14) and healthy controls (n = 14) as well as the central nervous system (CNS) of rats (20 per treatment arm) treated for 10 or 28 d with fluoxetine (10 mg/kg/d) or imipramine (20 mg/kg/d)." | 3.80 | Lower cortical serotonin 2A receptors in major depressive disorder, suicide and in rats after administration of imipramine. ( Dean, B; Everall, I; Gibbons, A; Jeon, WJ; Scarr, E; Seo, MS; Tawadros, N, 2014) |
| " Here, sucrose intake, forced swimming, immobility in the modified tail suspension test, novelty exploration, grooming, anxiety and locomotor activity were compared in naïve 3- and 18-month-old male C57BL/6 mice." | 3.78 | Anhedonic-like traits and lack of affective deficits in 18-month-old C57BL/6 mice: Implications for modeling elderly depression. ( Bachurin, S; Bolkunov, A; Kubatiev, A; Malatynska, E; Redkozubova, O; Steinbusch, HW; Strekalova, T; Vignisse, J; Yeritsyan, NB, 2012) |
| " He recovered after the resumption of imipramine but the visual hallucinations persisted." | 3.69 | Charles Bonnet syndrome with major depression in a Chinese middle-aged man. ( Fong, SY; Wing, YK, 1997) |
| "In-patients (n = 88) with major depressive disorder were randomized to 7-week treatment with imipramine or venlafaxine (phase I)." | 2.84 | A randomized clinical trial comparing two two-phase treatment strategies for in-patients with severe depression. ( Birkenhäger, TK; Hoogendijk, WJG; Kamperman, AM; van den Broek, WW; Vermeiden, M, 2017) |
| " Relapse and adverse events on both active drugs open up the risks of a prescribing cascade." | 2.82 | Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression. ( Abi-Jaoude, E; Healy, D; Jureidini, J; Le Noury, J; Nardo, JM; Raven, M; Tufanaru, C, 2016) |
| "In a sample of 34 patients with major depressive disorder, treated with antidepressants, the combined effect of treatment and natural course was examined over a period of 18 weeks with Ecological Momentary Assessment (EMA)." | 2.79 | Testing an mHealth momentary assessment Routine Outcome Monitoring application: a focus on restoration of daily life positive mood states. ( Bakker, RP; Barge, D; Delespaul, P; van Os, J, 2014) |
| "Treatment with imipramine decreased Stress-Sensitivity and increased Reward Experience (positive affect reactivity to positively appraised activities)." | 2.74 | Reduced stress-sensitivity or increased reward experience: the psychological mechanism of response to antidepressant medication. ( Barge-Schaapveld, DQ; de Vries, M; Mengelers, R; Nicolson, NA; Peeters, F; van Os, J; Wichers, MC, 2009) |
| "Patients with major depressive disorder or dysthymic disorder achieved similar clinical improvement in both treatment groups (mean MADRS ratings decrease in major depressive disorder from baseline to 6 months of 18." | 2.72 | Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine. ( Caramés, E; Gabarron, E; Garcia-Bayo, I; Haro, JM; Peñarrubia-Maria, MT; Pinto-Meza, A; Serrano-Blanco, A; Soler-Vila, M, 2006) |
| " The mean imipramine dosage was 209 mg/day (standard deviation: 91." | 2.72 | Imipramine is effective in preventing relapse in electroconvulsive therapy-responsive depressed inpatients with prior pharmacotherapy treatment failure: a randomized, placebo-controlled trial. ( Birkenhäger, TK; Bruijn, JA; Moleman, P; Mulder, PG; van den Broek, WW, 2006) |
| "Sixty nondiabetic patients with major depressive disorder (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) entered this randomized, double-blind study." | 2.71 | Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. ( Dashti-Khavidaki, S; Ghaeli, P; Kamkar, MZ; Mesbahi, M; Sadeghi, M; Shahsavand, E, 2004) |
| "Imipramine has often been used as positive control in studies investigating the efficacy of new antidepressants." | 2.71 | Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed? ( Birkenhäger, TK; Bruijn, JA; Moleman, P; van den Broek, WW; Vulto, AG, 2005) |
| "Sertraline was significantly superior in tolerability with less discontinuations due to adverse events (10." | 2.71 | Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study. ( Baca, E; García-Toro, M; González de Chávez, M; Pérez-Arnau, F; Porras-Chavarino, A, 2003) |
| " Adverse events were significantly less in patients treated with SAMe compared to those treated with IMI." | 2.70 | A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. ( Chiaie, RD; Pancheri, P; Scapicchio, P, 2002) |
| "Milnacipran was found to be of similar efficacy to imipramine." | 2.70 | A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. ( Ferrey, G; Tournoux, A; Van Amerongen, AP, 2002) |
| "imipramine." | 2.70 | Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. ( Davis, S; Friedman, ES; Harrison, W; Hirschfeld, RM; Keller, M; Koran, LM; Rush, J; Russell, JM, 2001) |
| " These results indicate that imipramine and sertraline are equally effective for the treatment of major depression in later life, although adverse reactions are more frequent among subjects treated with imipramine than with sertraline." | 2.70 | Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. ( Almeida, OP; Forlenza, OV; Hirata, ES; Stoppe, A, 2001) |
| "Major depressive disorder is one of the most common mental disorders in children and adolescents." | 2.53 | Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. ( Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X, 2016) |
| " A metaregression did not reveal a statistically significant relation between the mean moclobemide dosage for each study and the risk ratio for response rates." | 2.43 | A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. ( Fava, M; Papakostas, GI, 2006) |
| " The rate of discontinuation due to adverse effects with reboxetine was not significantly different from that observed with placebo in short-term studies." | 2.41 | Reboxetine: tolerability and safety profile in patients with major depression. ( Tanum, L, 2000) |
| "Decreased PGD2 levels in major depressive disorder are associated with depression-like behaviors." | 1.46 | Decreased Prostaglandin D2 Levels in Major Depressive Disorder Are Associated with Depression-Like Behaviors. ( Chu, C; Shen, Y; Wei, H; Xu, Q; Zhu, W, 2017) |
| "Patients with major depressive disorder (MDD) frequently also have alcohol use disorder (AUD) and they are more likely to experience symptomatic recurrence and resist treatment." | 1.42 | Influence of comorbid alcohol use disorder on treatment response of depressive patients. ( Hashimoto, E; Ishikawa, H; Saito, T; Tayama, M; Yamamoto, M, 2015) |
| "Ketamine is an anesthetic with antidepressant properties." | 1.42 | The positive effect on ketamine as a priming adjuvant in antidepressant treatment. ( Dalla, C; Ferreira, C; Kokras, N; Melo, A; Pêgo, JM; Sousa, N; Ventura-Silva, AP, 2015) |
| "Major depressive disorder is a chronic disabling disease, often triggered and exacerbated by stressors of a social nature." | 1.37 | Reduction in hippocampal neurogenesis after social defeat is long-lasting and responsive to late antidepressant treatment. ( Hoogendijk, WJ; Lucassen, PJ; Oomen, CA; Smit, AB; Spijker, S; Van Bokhoven, P, 2011) |
| " At maintenance phase immediately before relapse, average dosage was 42." | 1.35 | Adequacy of continuation and maintenance treatments for major depression in Japan. ( Akechi, T; Azuma, H; Fujita, A; Furukawa, TA; Kitamura, T; Takahashi, K, 2008) |
| "Thirty-six patients with major depressive disorder diagnosed according to DSM-IV, and 20 healthy control subjects were involved in the study." | 1.32 | P300 changes in major depressive disorders with and without psychotic features. ( Erdinc, E; Esel, E; Gonul, AS; Karaaslan, F; Oguz, A, 2003) |
| "Treatment with fluvoxamine did not result in alterations in the 24-h pattern of motor activity." | 1.31 | 24-Hour motor activity after treatment with imipramine or fluvoxamine in major depressive disorder. ( Bruijn, JA; Passchier, J; Pepplinkhuizen, L; Tulen, JH; Van Den Broek, WW; Volkers, AC, 2002) |
| "Mood disorders are the leading causes of morbidity and mortality in children and adolescence." | 1.31 | Mood disorders in children and adolescents: psychopharmacological treatment. ( Emslie, GJ; Mayes, TL, 2001) |
| " The achievement of such results with moderate doses might indicate a possible relationship between the optimal dosage of the antidepressive drug and the intensity of the mood disorder." | 1.26 | [Imipramine and neuro-psychiatry. Retrospective study of 557 out-patients treated in a neuro-psychiatric unit (author's transl)]. ( Boulenger, JP; Brion, S, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (23.13) | 18.7374 |
| 1990's | 12 (8.16) | 18.2507 |
| 2000's | 58 (39.46) | 29.6817 |
| 2010's | 41 (27.89) | 24.3611 |
| 2020's | 2 (1.36) | 2.80 |
| Authors | Studies |
|---|---|
| Stachowicz, K | 1 |
| Panczyszyn-Trzewik, P | 1 |
| Rzezniczek X, S | 1 |
| Sowa-Kucma, M | 2 |
| Rao, Y | 1 |
| Yang, R | 1 |
| Zhao, J | 1 |
| Cao, Q | 1 |
| Snippe, E | 1 |
| Viechtbauer, W | 1 |
| Geschwind, N | 2 |
| Klippel, A | 1 |
| de Jonge, P | 1 |
| Wichers, M | 2 |
| Vermeiden, M | 3 |
| Kamperman, AM | 2 |
| Hoogendijk, WJG | 1 |
| van den Broek, WW | 12 |
| Birkenhäger, TK | 11 |
| Chu, C | 1 |
| Wei, H | 1 |
| Zhu, W | 1 |
| Shen, Y | 1 |
| Xu, Q | 1 |
| Undurraga, J | 2 |
| Baldessarini, RJ | 2 |
| Golden, SA | 1 |
| Christoffel, DJ | 1 |
| Heshmati, M | 1 |
| Hodes, GE | 1 |
| Magida, J | 1 |
| Davis, K | 1 |
| Cahill, ME | 1 |
| Dias, C | 1 |
| Ribeiro, E | 1 |
| Ables, JL | 1 |
| Kennedy, PJ | 1 |
| Robison, AJ | 1 |
| Gonzalez-Maeso, J | 1 |
| Neve, RL | 1 |
| Turecki, G | 2 |
| Ghose, S | 1 |
| Tamminga, CA | 1 |
| Russo, SJ | 1 |
| Mulder, PG | 5 |
| Bruijn, JA | 9 |
| Dean, B | 3 |
| Tawadros, N | 1 |
| Seo, MS | 1 |
| Jeon, WJ | 2 |
| Everall, I | 1 |
| Scarr, E | 3 |
| Gibbons, A | 2 |
| Ren, L | 1 |
| Qian, X | 1 |
| Zhai, L | 1 |
| Sun, M | 1 |
| Miao, Z | 1 |
| Li, J | 1 |
| Xu, X | 1 |
| Hashimoto, E | 1 |
| Tayama, M | 1 |
| Ishikawa, H | 1 |
| Yamamoto, M | 1 |
| Saito, T | 1 |
| Vulink, ME | 1 |
| Wagner, GJ | 1 |
| Ngo, VK | 1 |
| Nakasujja, N | 1 |
| Akena, D | 1 |
| Aunon, F | 1 |
| Musisi, S | 1 |
| van Os, J | 3 |
| Delespaul, P | 1 |
| Barge, D | 1 |
| Bakker, RP | 1 |
| Berm, EJJ | 1 |
| Paardekooper, J | 1 |
| Brummel-Mulder, E | 1 |
| Hak, E | 1 |
| Wilffert, B | 1 |
| Maring, JG | 1 |
| Grosse, L | 1 |
| Carvalho, LA | 1 |
| Hoogendijk, WJ | 2 |
| Kushner, SA | 1 |
| Drexhage, HA | 1 |
| Bergink, V | 1 |
| Melo, A | 1 |
| Kokras, N | 1 |
| Dalla, C | 1 |
| Ferreira, C | 1 |
| Ventura-Silva, AP | 1 |
| Sousa, N | 1 |
| Pêgo, JM | 1 |
| Gressier, F | 1 |
| Rotenberg, S | 1 |
| Ait Tayeb, AEK | 1 |
| Colle, R | 1 |
| Hardy, P | 1 |
| Becquemont, L | 1 |
| Verstuyft, C | 1 |
| Corruble, E | 2 |
| Le Noury, J | 3 |
| Nardo, JM | 3 |
| Healy, D | 3 |
| Jureidini, J | 3 |
| Raven, M | 3 |
| Tufanaru, C | 3 |
| Abi-Jaoude, E | 3 |
| Linden, DE | 1 |
| Sasich, LD | 1 |
| Gibbons, AS | 1 |
| McOmish, CE | 1 |
| Pavey, G | 1 |
| Hopper, S | 1 |
| Udawela, M | 1 |
| Cipriani, A | 1 |
| Zhou, X | 1 |
| Del Giovane, C | 1 |
| Hetrick, SE | 1 |
| Qin, B | 1 |
| Whittington, C | 1 |
| Coghill, D | 1 |
| Zhang, Y | 1 |
| Hazell, P | 1 |
| Leucht, S | 1 |
| Cuijpers, P | 1 |
| Pu, J | 1 |
| Cohen, D | 1 |
| Ravindran, AV | 1 |
| Liu, Y | 1 |
| Michael, KD | 1 |
| Yang, L | 1 |
| Liu, L | 1 |
| Xie, P | 1 |
| Mulder, R | 1 |
| Rucklidge, JJ | 1 |
| Toop, L | 1 |
| Tashiro, T | 1 |
| Murakami, Y | 1 |
| Mouri, A | 1 |
| Imamura, Y | 1 |
| Nabeshima, T | 1 |
| Yamamoto, Y | 1 |
| Saito, K | 1 |
| Pluijms, EM | 1 |
| Ergün, Y | 1 |
| Orhan, FO | 1 |
| Karaaslan, MF | 1 |
| Hill, MN | 1 |
| Carrier, EJ | 1 |
| McLaughlin, RJ | 1 |
| Morrish, AC | 1 |
| Meier, SE | 1 |
| Hillard, CJ | 1 |
| Gorzalka, BB | 1 |
| Furukawa, TA | 3 |
| Yoshimura, R | 1 |
| Harai, H | 1 |
| Imaizumi, T | 1 |
| Takeuchi, H | 1 |
| Kitamura, T | 3 |
| Takahashi, K | 3 |
| Lutz, W | 1 |
| Stulz, N | 1 |
| Köck, K | 1 |
| Siwek, M | 2 |
| Dudek, D | 2 |
| Paul, IA | 1 |
| Zieba, A | 2 |
| Popik, P | 2 |
| Pilc, A | 2 |
| Nowak, G | 2 |
| Uezato, A | 1 |
| Meador-Woodruff, JH | 1 |
| McCullumsmith, RE | 1 |
| Wijkstra, J | 1 |
| Burger, H | 1 |
| Janzing, JG | 1 |
| Boks, MP | 1 |
| van der Loos, ML | 1 |
| Breteler, LM | 1 |
| Verkes, RJ | 1 |
| Nolen, WA | 1 |
| Eby, GA | 1 |
| Eby, KL | 1 |
| Elkin, I | 1 |
| Schlegel-Zawadzka, M | 1 |
| Morawska, A | 1 |
| Piekoszewski, W | 1 |
| Opoka, W | 1 |
| Inoue, T | 1 |
| Abekawa, T | 1 |
| Nakagawa, S | 1 |
| Suzuki, K | 1 |
| Tanaka, T | 2 |
| Kitaichi, Y | 1 |
| Boku, S | 1 |
| Nakato, Y | 1 |
| Toda, H | 1 |
| Koyama, T | 1 |
| Nicolson, NA | 2 |
| Peeters, F | 2 |
| Barge-Schaapveld, D | 1 |
| Van Bokhoven, P | 1 |
| Oomen, CA | 1 |
| Smit, AB | 1 |
| Lucassen, PJ | 1 |
| Spijker, S | 1 |
| Underwood, MD | 1 |
| Kassir, SA | 1 |
| Bakalian, MJ | 1 |
| Galfalvy, H | 1 |
| Mann, JJ | 1 |
| Arango, V | 1 |
| Ferreira, FR | 1 |
| Oliveira, AM | 1 |
| Dinarte, AR | 1 |
| Pinheiro, DG | 1 |
| Greene, LJ | 1 |
| Silva, WA | 1 |
| Joca, SR | 1 |
| Guimarães, FS | 1 |
| Stewart, JG | 1 |
| Harkness, KL | 2 |
| Malatynska, E | 1 |
| Steinbusch, HW | 1 |
| Redkozubova, O | 1 |
| Bolkunov, A | 1 |
| Kubatiev, A | 1 |
| Yeritsyan, NB | 1 |
| Vignisse, J | 1 |
| Bachurin, S | 1 |
| Strekalova, T | 1 |
| Nagasawa, M | 1 |
| Murakami, T | 1 |
| Tomonaga, S | 1 |
| Furuse, M | 1 |
| Tondo, L | 1 |
| Schalkwijk, S | 1 |
| Vieta, E | 2 |
| Volkers, AC | 3 |
| Tulen, JH | 3 |
| Passchier, J | 2 |
| Pepplinkhuizen, L | 2 |
| Ross, DC | 1 |
| Quitkin, FM | 3 |
| Klein, DF | 4 |
| Van Amerongen, AP | 1 |
| Ferrey, G | 1 |
| Tournoux, A | 2 |
| Correll, CU | 1 |
| Pleak, RR | 1 |
| Silveira, R | 1 |
| Jainer, AK | 1 |
| Singh, R | 1 |
| Delle Chiaie, R | 1 |
| Pancheri, P | 2 |
| Scapicchio, P | 2 |
| Chiaie, RD | 1 |
| Karaaslan, F | 1 |
| Gonul, AS | 1 |
| Oguz, A | 1 |
| Erdinc, E | 1 |
| Esel, E | 1 |
| Layne, AE | 1 |
| Bernstein, GA | 3 |
| Egan, EA | 1 |
| Kushner, MG | 2 |
| Baca, E | 1 |
| González de Chávez, M | 1 |
| García-Toro, M | 1 |
| Pérez-Arnau, F | 1 |
| Porras-Chavarino, A | 1 |
| FREYHAN, FA | 1 |
| KAMMERER, T | 1 |
| EBTINGER, R | 1 |
| NOEL, C | 1 |
| ARIEFF, AJ | 1 |
| ADAMS, J | 1 |
| CRAWFORD, J | 1 |
| TOFTE, F | 1 |
| NAGY, AT | 1 |
| PERTORINI, R | 1 |
| KRAKOWSKI, AJ | 1 |
| BARCIASALORIO, D | 1 |
| ROPERT, R | 1 |
| BASTECKY, J | 1 |
| JANIK, A | 1 |
| ALNAES, R | 1 |
| KRISTIANSEN, J | 1 |
| BRANDNER, M | 1 |
| GREENBLATT, M | 1 |
| GROSSER, GH | 1 |
| WECHSLER, H | 1 |
| POELDINGER, W | 1 |
| HARDI, I | 1 |
| MARINOW, A | 1 |
| STRAKHOV, AP | 1 |
| TIMOFEEVA, AN | 1 |
| LIPSKAIA, LA | 1 |
| SOERGEL, HJ | 1 |
| HOENIG, J | 1 |
| VISRAM, S | 1 |
| HANKOFF, LD | 1 |
| GUNDLACH, RH | 1 |
| PALEY, HM | 1 |
| RUDORFER, L | 1 |
| Bruyn, JA | 1 |
| Gómez-Gil, E | 1 |
| Gastó, C | 2 |
| Carretero, M | 1 |
| Díaz-Ricart, M | 1 |
| Salamero, M | 1 |
| Navinés, R | 1 |
| Escolar, G | 1 |
| Lopez-Ibor, JJ | 1 |
| Conesa, A | 1 |
| Ghaeli, P | 1 |
| Shahsavand, E | 1 |
| Mesbahi, M | 1 |
| Kamkar, MZ | 1 |
| Sadeghi, M | 1 |
| Dashti-Khavidaki, S | 1 |
| Moleman, P | 5 |
| McGrath, PJ | 2 |
| Stewart, JW | 2 |
| Deliyannides, D | 1 |
| Taylor, BP | 1 |
| Davies, CA | 1 |
| Vulto, AG | 1 |
| Mendhekar, DN | 1 |
| Serrano-Blanco, A | 1 |
| Gabarron, E | 1 |
| Garcia-Bayo, I | 1 |
| Soler-Vila, M | 1 |
| Caramés, E | 1 |
| Peñarrubia-Maria, MT | 1 |
| Pinto-Meza, A | 1 |
| Haro, JM | 1 |
| Monroe, SM | 2 |
| Torres, LD | 1 |
| Guillaumot, J | 1 |
| Roberts, JE | 2 |
| Frank, E | 2 |
| Kupfer, D | 1 |
| Ghaffari-Nejad, A | 1 |
| Toofani, K | 1 |
| Yoshida, K | 1 |
| Sugawara, Y | 1 |
| Higuchi, H | 1 |
| Papakostas, GI | 1 |
| Fava, M | 1 |
| Piper, WE | 1 |
| Ogrodniczuk, JS | 1 |
| Joyce, AS | 1 |
| Weideman, R | 1 |
| Rosie, JS | 1 |
| Berlim, MT | 1 |
| Harvey, AT | 1 |
| Silkey, BS | 1 |
| Kornstein, SG | 3 |
| Clary, CM | 1 |
| González, A | 1 |
| Fazzino, F | 1 |
| Castillo, M | 1 |
| Mata, S | 1 |
| Lima, L | 1 |
| Parry, BL | 1 |
| Fujita, A | 1 |
| Azuma, H | 1 |
| Akechi, T | 1 |
| Cankurtaran, ES | 1 |
| Ozalp, E | 1 |
| Soygur, H | 1 |
| Akbiyik, DI | 1 |
| Turhan, L | 1 |
| Alkis, N | 1 |
| Glick, ID | 1 |
| Siris, SG | 1 |
| Davis, JM | 1 |
| Wichers, MC | 1 |
| Barge-Schaapveld, DQ | 1 |
| de Vries, M | 1 |
| Mengelers, R | 1 |
| Brion, S | 1 |
| Boulenger, JP | 1 |
| Molcan, J | 1 |
| Novotný, V | 1 |
| Nábĕlek, L | 1 |
| Morinobu, S | 1 |
| Kawakatsu, S | 1 |
| Totsuka, S | 1 |
| Koyama, E | 1 |
| Chiba, K | 1 |
| Ishizaki, T | 1 |
| Kubota, T | 1 |
| Steiger, A | 1 |
| Holsboer, F | 1 |
| Fong, SY | 1 |
| Wing, YK | 1 |
| Tignol, J | 1 |
| Pujol-Domenech, J | 1 |
| Chartres, JP | 1 |
| Léger, JM | 1 |
| Plétan, Y | 1 |
| Tonelli, I | 1 |
| Pezous, N | 1 |
| Rajagopalan, M | 1 |
| Tomiyoshi, R | 1 |
| Kamei, K | 1 |
| Muraoka, S | 1 |
| Muneoka, K | 1 |
| Takigawa, M | 1 |
| Guelfi, JD | 1 |
| Feeley, M | 1 |
| DeRubeis, RJ | 1 |
| Gelfand, LA | 1 |
| Bruder, GE | 1 |
| Gurguis, GN | 2 |
| Vo, SP | 2 |
| Griffith, JM | 2 |
| Rush, AJ | 4 |
| Borchardt, CM | 1 |
| Perwien, AR | 1 |
| Crosby, RD | 1 |
| Thuras, PD | 1 |
| Last, CG | 1 |
| Anderson, LK | 1 |
| Hektner, JM | 1 |
| Realmuto, GM | 1 |
| Nieto, E | 1 |
| Alvarez, L | 1 |
| Torra, M | 1 |
| Colom, F | 1 |
| Bekaroğlu, M | 1 |
| Değer, O | 1 |
| Karahan, SC | 1 |
| Bilici, M | 1 |
| Soylu, C | 1 |
| Orem, A | 1 |
| Tanum, L | 1 |
| Siris, S | 1 |
| Pollack, S | 1 |
| Bermanzohn, P | 1 |
| Stronger, R | 1 |
| Montgomery, SA | 1 |
| Judge, R | 1 |
| McQuaid, JR | 1 |
| Kupfer, DJ | 1 |
| Russell, JM | 2 |
| Koran, LM | 3 |
| Rush, J | 1 |
| Hirschfeld, RM | 3 |
| Harrison, W | 2 |
| Friedman, ES | 1 |
| Davis, S | 1 |
| Keller, M | 1 |
| Forlenza, OV | 1 |
| Almeida, OP | 1 |
| Stoppe, A | 1 |
| Hirata, ES | 1 |
| Gelenberg, AJ | 2 |
| Howland, RH | 2 |
| Friedman, RA | 1 |
| DeBattista, C | 1 |
| Klein, D | 1 |
| Kocsis, JH | 2 |
| Schatzberg, AF | 2 |
| Thase, ME | 2 |
| LaVange, LM | 2 |
| Keller, MB | 2 |
| Emslie, GJ | 1 |
| Mayes, TL | 1 |
| Martinez, JM | 1 |
| Kent, JM | 1 |
| Coplan, JD | 1 |
| Browne, ST | 1 |
| Papp, LA | 1 |
| Sullivan, GM | 1 |
| Kleber, M | 1 |
| Perepletchikova, F | 1 |
| Fyer, AJ | 1 |
| Gorman, JM | 1 |
| Klein, DN | 1 |
| Fawcett, J | 1 |
| Prasko, J | 1 |
| Horacek, J | 1 |
| Klaschka, J | 1 |
| Kosova, J | 1 |
| Ondrackova, I | 1 |
| Sipek, J | 1 |
| Litvinova, NM | 1 |
| Kabachenko, EN | 1 |
| Zelikman, TIa | 1 |
| Shekhtman, ML | 1 |
| Hekimian, LJ | 1 |
| Gershon, S | 1 |
| Floyd, A | 1 |
| Fracchia, J | 1 |
| Sheppard, C | 1 |
| Merlis, S | 1 |
| Vinarová, E | 1 |
| Vinar, O | 1 |
| Radzuweit, H | 1 |
| Knorr, W | 1 |
| Sedivec, V | 1 |
| Valenová, Z | 1 |
| Paceltová, L | 1 |
| Post, F | 1 |
| Kramer, M | 1 |
| Whitman, RM | 1 |
| Baldridge, W | 1 |
| Lansky, L | 1 |
| Rosenblatt, S | 1 |
| Chanley, JD | 1 |
| Bilikiewicz, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| Development and Evaluation of an Ecological Momentary Assessment (EMA) Baseline Screening System for Therapists Who Treat Youths With Depressive Symptoms[NCT04830527] | 60 participants (Actual) | Interventional | 2020-11-24 | Terminated (stopped due to The study was terminated early due to the difficulty in recruiting cases during a pandemic period.) | |||
| A Prospective Randomized Controlled Trial of Electroconvulsive Therapy With Ketamine Anesthesia (Standard Therapy) and High Intensity Ketamine With Electroconvulsive Therapy Rescue for Treatment-Resistant Depression - EAST HIKER Trial[NCT03272698] | Phase 4 | 62 participants (Anticipated) | Interventional | 2017-09-01 | Recruiting | ||
| Subanesthetic Sevoflurane for Treatment-Resistant Depression: A Proof-of-Concept Trial[NCT05008939] | 15 participants (Anticipated) | Interventional | 2021-08-31 | Not yet recruiting | |||
| Computational Psychiatric Approach for Prognosis of Medication-Resistant Depression[NCT04189939] | 144 participants (Anticipated) | Observational | 2020-03-09 | Recruiting | |||
| Clinical Effects of Electroconvulsive Therapy in Severe Depression and Concomitant Changes in Cerebral Glucose Metabolism - an Exploratory Study[NCT01514435] | 13 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment[NCT00296777] | Phase 4 | 28 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Dichotic Listening as a Predictor of Placebo and Medication Response in Depression[NCT00296725] | Phase 1/Phase 2 | 25 participants (Actual) | Interventional | 1994-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The HAM-D is a commonly used measure of the severity of depression. While several versions exist consisting of different numbers of items, virtually all include the original 17. Each item is scored from on a 3 or 5 point scale (so, from 0-2 or 0-4), with 0 indicating the item is not present and the highest item score indicating it is present nearly all the time to the severest extent. Item scores are added to obtain a total HAM-D score. Minimum possible score is 0 (indicating none of the 17 items is present), maximal possible score is 52. By convention, scores of <=7 are accepted as indicating remission and scores that have decreased >= 50% from pre-treatment indicate positive response. Higher scores indicate worse depression, while lower scores indicate milder depression or lack of depressive symptoms." (NCT00296725)
Timeframe: 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Fluoxetine | 10 |
| Imipramine | 9 |
"The CGI consists of two ratings: 1) Global Severity (CGI-S) and 2) Global Improvement (CGI-I), both having seven possible ratings, each from 1-7. Ratings on the CGI-S are: 1=No psychopathology 2=Minimal psychopathology 3=Mild psychopathology 4=Moderate psychopathology 5=Moderately severe psychopathology 6=Severe psychopathology 7 Extreme psychopathology. CGI-I ratings are rated for how the past week's psychopathology compares to the week immediately prior to start of treatment and includes: 1=Very much improved 2=much improved 3=minimally improved 4=Unchanged 5=minimally worse 6=much worse 7=very much worse. Scores on both thus range from 1-7 with lower scores indicating less psychopathology/greater improvement, respectively, and higher scores indicating more psychopathology/less improvement, respectively. We define response as a CGI-I of 1 or 2; nonresponse is all other ratings (i.e., CGI-I = 3 or higher." (NCT00296725)
Timeframe: 6 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Fluoxetine | 7 |
| Imipramine | 4 |
9 reviews available for imipramine and Depressive Disorder, Major
| Article | Year |
|---|---|
Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Dul | 2022 |
Direct comparison of tricyclic and serotonin-reuptake inhibitor antidepressants in randomized head-to-head trials in acute major depression: Systematic review and meta-analysis.
Topics: Antidepressive Agents, Tricyclic; Depression; Depressive Disorder, Major; Double-Blind Method; Human | 2017 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Magnesium for treatment-resistant depression: a review and hypothesis.
Topics: Animals; Antidepressive Agents, Tricyclic; Brain; Clinical Trials as Topic; D-Aspartic Acid; Depress | 2010 |
A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Topics: Depressive Disorder, Major; Disorders of Excessive Somnolence; Fatigue; Headache; Humans; Imipramine | 2006 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Dose-Response Relationshi | 2007 |
Perimenopausal depression.
Topics: Administration, Cutaneous; Combined Modality Therapy; Comorbidity; Depression, Postpartum; Depressiv | 2008 |
[Is there a relationship between clinical efficacy and antidepressant dosage in major depression?].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv | 1999 |
Reboxetine: tolerability and safety profile in patients with major depression.
Topics: Adrenergic Uptake Inhibitors; Age Factors; Antidepressive Agents; Cytochrome P-450 Enzyme System; De | 2000 |
50 trials available for imipramine and Depressive Disorder, Major
| Article | Year |
|---|---|
A randomized clinical trial comparing two two-phase treatment strategies for in-patients with severe depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combina | 2017 |
A double-blind randomized study comparing plasma level-targeted dose imipramine and high-dose venlafaxine in depressed inpatients.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Do | 2013 |
Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients.
Topics: Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statis | 2015 |
Testing an mHealth momentary assessment Routine Outcome Monitoring application: a focus on restoration of daily life positive mood states.
Topics: Adult; Affect; Antidepressive Agents; Computer Systems; Depressive Disorder, Major; Humans; Imiprami | 2014 |
Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Data Interpretat | 2015 |
Restoring Study 329: Paroxetine neither effective nor safe for adolescents.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-Blind Method; Femal | 2016 |
Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Double-Blin | 2016 |
Patterns of early change and their relationship to outcome and follow-up among patients with major depressive disorders.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cognitive Behaviora | 2009 |
Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Response Relationship, Dru | 2009 |
Long-term response to successful acute pharmacological treatment of psychotic depression.
Topics: Adult; Affective Disorders, Psychotic; Antidepressive Agents; Antipsychotic Agents; Cyclohexanols; D | 2010 |
Serum zinc level in depressed patients during zinc supplementation of imipramine treatment.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-Blind Method | 2010 |
Early improvement in positive rather than negative emotion predicts remission from depression after pharmacotherapy.
Topics: Adult; Affect; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; | 2011 |
Symptom specificity in the acute treatment of Major Depressive Disorder: a re-analysis of the treatment of depression collaborative research program.
Topics: Adult; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Di | 2012 |
A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression.
Topics: Adult; Aged; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; | 2002 |
Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-B | 2002 |
A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorde | 2002 |
Predictors of treatment response in anxious-depressed adolescents with school refusal.
Topics: Adolescent; Adolescent Behavior; Antidepressive Agents, Tricyclic; Anxiety Disorders; Child; Cogniti | 2003 |
Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Depressive Disorder, Major; Dysthymic Disorder; Femal | 2003 |
Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder.
Topics: Adult; Affect; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Aut | 2004 |
Decrease of the platelet 5-HT2A receptor function by long-term imipramine treatment in endogenous depression.
Topics: Adult; Antidepressive Agents, Tricyclic; Blood Platelets; Depressive Disorder, Major; Drug Administr | 2004 |
A comparative study of milnacipran and imipramine in the treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Double-Bl | 2004 |
Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Blood Glucose; Depressive Disorder, Major; Double-Bli | 2004 |
A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive | 2004 |
Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Drug Administration Sched | 2004 |
Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Clinical Protocols; Depressive Disorder, Major; Doubl | 2005 |
Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Response Relationshi | 2005 |
Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine.
Topics: Adult; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Depressive Disorder, Major; Double-B | 2006 |
Imipramine is effective in preventing relapse in electroconvulsive therapy-responsive depressed inpatients with prior pharmacotherapy treatment failure: a randomized, placebo-controlled trial.
Topics: Adult; Antidepressive Agents, Tricyclic; Combined Modality Therapy; Depressive Disorder, Major; Doub | 2006 |
Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; B | 2006 |
Group composition and group therapy for complicated grief.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; Grief; Group Proc | 2007 |
Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status.
Topics: Adult; Cross-Over Studies; Depressive Disorder, Major; Disease Progression; Double-Blind Method; Dys | 2007 |
Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine.
Topics: Adaptation, Psychological; Adjustment Disorders; Adrenergic alpha-Antagonists; Adult; Antidepressive | 2008 |
Reduced stress-sensitivity or increased reward experience: the psychological mechanism of response to antidepressant medication.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Fe | 2009 |
Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.
Topics: Adrenergic Uptake Inhibitors; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, | 1998 |
Comparison of venlafaxine and imipramine in depressive illness.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexano | 1998 |
The temporal relation of adherence and alliance to symptom change in cognitive therapy for depression.
Topics: Adult; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Combined Modality Therapy; De | 1999 |
Do tricyclic responders have different brain laterality?
Topics: Antidepressive Agents, Tricyclic; Brain; Depressive Disorder, Major; Dichotic Listening Tests; Doubl | 1999 |
Do tricyclic responders have different brain laterality?
Topics: Antidepressive Agents, Tricyclic; Brain; Depressive Disorder, Major; Dichotic Listening Tests; Doubl | 1999 |
Do tricyclic responders have different brain laterality?
Topics: Antidepressive Agents, Tricyclic; Brain; Depressive Disorder, Major; Dichotic Listening Tests; Doubl | 1999 |
Do tricyclic responders have different brain laterality?
Topics: Antidepressive Agents, Tricyclic; Brain; Depressive Disorder, Major; Dichotic Listening Tests; Doubl | 1999 |
Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; G | 1999 |
Imipramine plus cognitive-behavioral therapy in the treatment of school refusal.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Child; Cognitive Behavioral Therapy; Combined Modality | 2000 |
Imipramine compliance in adolescents.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Child; Cognitive Behavioral Therapy; Combined Modality | 2000 |
Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benztropine; Depressive Disorder, Maj | 2000 |
Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Analysis of Variance; Anxiety Disorders; Chronic Disease; | 2001 |
Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Brazil; Cost-Benefit Analysis; Depres | 2001 |
Sertraline versus imipramine to prevent relapse in chronic depression.
Topics: Adult; Aged; Chronic Disease; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; D | 2001 |
Respiratory variability in panic disorder.
Topics: Adult; Arousal; Autonomic Nervous System; Carbon Dioxide; Cognitive Behavioral Therapy; Depressive D | 2001 |
Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression.
Topics: Adult; Cross-Over Studies; Depressive Disorder, Major; Dysthymic Disorder; Female; Humans; Imipramin | 2002 |
Bright light therapy and/or imipramine for inpatients with recurrent non-seasonal depression.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-Blind Method; Female; Hu | 2002 |
Cyprolidol and imipramine: a double-blind controlled study in endogenous depression.
Topics: Antidepressive Agents; Arteries; Blood Pressure; Clinical Trials as Topic; Depression; Depressive Di | 1969 |
Combination medications in psychiatric treatment: patterns in a group of elderly hospital patients.
Topics: Age Factors; Aged; Amitriptyline; Antidepressive Agents; Antihypertensive Agents; Antisocial Persona | 1971 |
Chlorpromazine-procyclidine combination, imipramine and placebo in depressive disorders.
Topics: Bipolar Disorder; Chlorpromazine; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Imip | 1966 |
88 other studies available for imipramine and Depressive Disorder, Major
| Article | Year |
|---|---|
Cyclooxygenase-2 inhibition affects the expression of down syndrom cell adhesion molecule via interaction with metabotropic glutamate receptor 5.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arachidonic Acid; Cell Adhesion; C | 2022 |
The Impact of Treatments for Depression on the Dynamic Network Structure of Mental States: Two Randomized Controlled Trials.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Depressive Disord | 2017 |
Decreased Prostaglandin D2 Levels in Major Depressive Disorder Are Associated with Depression-Like Behaviors.
Topics: Adolescent; Adult; Animals; Antidepressive Agents, Tricyclic; Antioxidants; Brain; Chromatography, L | 2017 |
Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression.
Topics: Actin Depolymerizing Factors; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Dendritic | 2013 |
Lower cortical serotonin 2A receptors in major depressive disorder, suicide and in rats after administration of imipramine.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antidepressive Agents; Antipsychotic Agents; Bipolar Disord | 2014 |
Loss of Ahi1 impairs neurotransmitter release and causes depressive behaviors in mice.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Behavior, Animal; Depressive Disorder, Major; Dopami | 2014 |
Influence of comorbid alcohol use disorder on treatment response of depressive patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Antidepressive Agents; Depressive Disorder, Major; Female; Foll | 2015 |
Impact of antidepressant therapy on cognitive aspects of work, condom use, and psychosocial well-being among HIV clients in Uganda.
Topics: Adult; Antidepressive Agents; Cognition Disorders; Condoms; Depressive Disorder, Major; Developing C | 2014 |
A simple dried blood spot method for therapeutic drug monitoring of the tricyclic antidepressants amitriptyline, nortriptyline, imipramine, clomipramine, and their active metabolites using LC-MS/MS.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Biotransformation; Calibration; Chromatography, Liq | 2015 |
Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricy | 2016 |
The positive effect on ketamine as a priming adjuvant in antidepressant treatment.
Topics: Animals; Antidepressive Agents; Anxiety; Aspartic Acid; Behavior, Animal; Brain; Depression; Depress | 2015 |
Tobacco Consumption Concerns With the Use of CYP1A2 Metabolized Antidepressants.
Topics: Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP1A2; Depressive Disorder, Major; Female; Genot | 2015 |
Restoring Study 329: results differ with the adverse event classification system used.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; | 2015 |
Authors' reply to Sasich and Linden.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; | 2015 |
Paroxetine and Study 329: what we already knew and when.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; | 2015 |
Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants.
Topics: Animals; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cerebral Cortex; Depressive Diso | 2016 |
Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia.
Topics: Amino Acids; Animals; Antidepressive Agents; Bipolar Disorder; Brain; Depressive Disorder, Major; Ex | 2016 |
Both paroxetine and imipramine appear to be ineffective in adolescents with major depression, furthermore doubts have risen about their safety.
Topics: Adolescent; Antidepressive Agents; Depressive Disorder, Major; Humans; Imipramine; Paroxetine | 2016 |
Kynurenine 3-monooxygenase is implicated in antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions.
Topics: Animals; Antidepressive Agents; Biogenic Monoamines; Depressive Disorder, Major; Disease Models, Ani | 2017 |
Possible Synergy Between Electroconvulsive Therapy and Imipramine: A Case Report.
Topics: Antidepressive Agents, Tricyclic; Combined Modality Therapy; Depressive Disorder, Major; Electroconv | 2016 |
Combination therapy of imipramine and melatonin: additive antidepressant effect in mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Dose-Response Re | 2008 |
Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.
Topics: Analgesics; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arachidonic Acids; Bra | 2008 |
How many well vs. unwell days can you expect over 10 years, once you become depressed?
Topics: Adult; Antidepressive Agents; Cognitive Behavioral Therapy; Depressive Disorder, Major; Diagnostic a | 2009 |
Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia.
Topics: Adult; Aged; Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Antipsychotic Agents; | 2009 |
Depression severity and effect of antidepressant medications.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Imipramine; Placebo Effect; Reproducibili | 2010 |
Long-term naturalistic follow-up of lithium augmentation: relevance to bipolarity.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Bipolar Disorder; Depressive Disorder, Majo | 2011 |
Reduction in hippocampal neurogenesis after social defeat is long-lasting and responsive to late antidepressant treatment.
Topics: Adult; Animals; Antidepressive Agents, Tricyclic; Cell Differentiation; Cell Survival; Conditioning, | 2011 |
Neuron density and serotonin receptor binding in prefrontal cortex in suicide.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adolescent; Adult; Aged; Autoradiography; Case-Control Studi | 2012 |
Changes in hippocampal gene expression by 7-nitroindazole in rats submitted to forced swimming stress.
Topics: Animals; Depressive Disorder, Major; Disease Models, Animal; Gene Expression Regulation; Hippocampus | 2012 |
Anhedonic-like traits and lack of affective deficits in 18-month-old C57BL/6 mice: Implications for modeling elderly depression.
Topics: Aging; Anhedonia; Animals; Antidepressive Agents, Tricyclic; Anxiety; Behavior, Animal; Depressive D | 2012 |
The impact of chronic imipramine treatment on amino acid concentrations in the hippocampus of mice.
Topics: Amino Acids; Animals; Antidepressive Agents, Tricyclic; Body Weight; Brain Chemistry; Cerebral Corte | 2012 |
Re-analysis of the earliest controlled trials of imipramine.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Imipramine; Randomized Controlled Trials | 2013 |
24-Hour motor activity after treatment with imipramine or fluvoxamine in major depressive disorder.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Imipramine; M | 2002 |
A typological model for estimation of drug and placebo effects in depression.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Fluoxetine; Humans; Imi | 2002 |
Paroxetine in the treatment of adolescent major depression.
Topics: Adolescent; Depressive Disorder, Major; Drug Monitoring; Humans; Imipramine; Paroxetine; Selective S | 2002 |
Paroxetine in the treatment of adolescent major depression.
Topics: Adolescent; Depressive Disorder, Major; Drug Monitoring; Humans; Imipramine; Paroxetine; Selective S | 2002 |
P300 changes in major depressive disorders with and without psychotic features.
Topics: Adult; Affective Disorders, Psychotic; Antidepressive Agents; Antipsychotic Agents; Cerebral Cortex; | 2003 |
Clinical effectiveness of tofranil in the treatment of depressive psychoses.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Imipramine; Mental Disorders; Psychotic Disord | 1959 |
[A delusion of negation in a young adult. Changes following action of various therapeutic agents (narcoanalysis, imipramine, electroshock, Sakel's cure)].
Topics: Convulsive Therapy; Delusions; Depressive Disorder, Major; Electroconvulsive Therapy; Electroshock; | 1960 |
Treatment of recurrent mental depression with imipramine.
Topics: Chronic Disease; Depression; Depressive Disorder; Depressive Disorder, Major; Imipramine | 1961 |
[Tofranil treatment of dysphoria in criminals].
Topics: Criminal Psychology; Criminals; Depression; Depressive Disorder; Depressive Disorder, Major; Imipram | 1961 |
[On the clinical use of Melipramin (imipramine)].
Topics: Depressive Disorder, Major; Humans; Imipramine; Psychotic Disorders; Schizophrenia | 1963 |
TREATMENT OF SEVERE DEPRESSION WITH DESIPRAMINE, A METABOLITE OF IMIPRAMINE.
Topics: Adolescent; Antidepressive Agents; Brain Diseases; Depression; Depressive Disorder; Depressive Disor | 1963 |
[STUDY OF CEREBRAL HEMODYNAMICS IN THE DEPRESSIVE STATES].
Topics: Amitriptyline; Bipolar Disorder; Cerebrovascular Circulation; Depression; Depressive Disorder; Depre | 1963 |
[OUR CLINICAL EXPERIENCE WITH AMITRIPTYLINE].
Topics: Adolescent; Amitriptyline; Bipolar Disorder; Depression; Depressive Disorder; Depressive Disorder, M | 1963 |
[MANIA-LIKE SYNDROME AFTER TOFRANIL].
Topics: Antisocial Personality Disorder; Bipolar Disorder; Depression; Depressive Disorder, Major; Imipramin | 1963 |
[DESMETHYLIMIPRAMINE (PERTOFRAN) IN THE TREATMENT OF DEPRESSIONS. A CLINICAL AND PSYCHODYNAMIC APPRAISAL].
Topics: Antidepressive Agents; Biomedical Research; Bipolar Disorder; Chlorpromazine; Depression; Depressive | 1963 |
[METHODS FOR EVALUATING ANTIDEPRESSIVE SUBSTANCES WITH SPECIAL REFERENCE TO MONOCHLORO-IMIPRAMINE G34586].
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Imipramine; Pharmacology; Psychotic Disor | 1964 |
DIFFERENTIAL RESPONSE OF HOSPITALIZED DEPRESSED PATIENTS TO SOMATIC THERAPY.
Topics: Bipolar Disorder; Depression; Depressive Disorder; Depressive Disorder, Major; Electroconvulsive The | 1964 |
[LAROXYL (AMITRIPTYLINE), A THYMOLEPTIC WITH A NEUROLEPTIC EFFICACY COMPONENT].
Topics: Amitriptyline; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Chlordiazepoxide; Chlo | 1963 |
[DYNAMIC STUDIES ON DRAWING IN THE COURSE OF TREATMENT WITH PSYCHOTROPIC AGENTS].
Topics: Antisocial Personality Disorder; Bipolar Disorder; Depressive Disorder, Major; Imipramine; Mental Di | 1964 |
[TREATMENT OF DEPRESSION WITH TOFRANIL WITH REGARD TO THE DRAWING TEST].
Topics: Bipolar Disorder; Chlorpromazine; Depression; Depressive Disorder; Depressive Disorder, Major; Human | 1964 |
[PECULIARITIES OF THE PHOTOERYTHEMIC SKIN REACTION IN PATIENTS WITH MANIC-DEPRESSIVE CONDITIONS AND ITS DYNAMICS DURING THE COURSE OF TREATMENT].
Topics: Anxiety; Anxiety Disorders; Bipolar Disorder; Chlorpromazine; Depression; Depressive Disorder; Depre | 1963 |
[BARBAMYL-TOFRANIL TEST IN THE EVALUATION OF THE DEPRESSIVE STATE].
Topics: Amobarbital; Anxiety; Anxiety Disorders; Bipolar Disorder; Delirium; Delusions; Depression; Depressi | 1963 |
[ON CLINICAL EXPERIENCES WITH MELIPRAMINE].
Topics: Antidepressive Agents; Antisocial Personality Disorder; Bipolar Disorder; Depressive Disorder, Major | 1964 |
AMITRIPTYLINE VERSUS IMIPRAMINE IN DEPRESSIVE PSYCHOSES.
Topics: Amitriptyline; Biomedical Research; Bipolar Disorder; Depression; Depressive Disorder; Depressive Di | 1964 |
DIPHENHYDRAMINE AS AN ANTIDEPRESSANT: A NEGATIVE FINDING.
Topics: Antidepressive Agents; Biomedical Research; Bipolar Disorder; Depressive Disorder, Major; Diphenhydr | 1964 |
Imipramine monotherapy-induced Hyperpigmentation in an adolescent girl.
Topics: Adult; Antidepressive Agents, Tricyclic; Biopsy; Depressive Disorder, Major; Diagnosis, Differential | 2005 |
Life stress and the long-term treatment course of recurrent depression: III. Nonsevere life events predict recurrence for medicated patients over 3 years.
Topics: Adult; Antidepressive Agents, Tricyclic; Combined Modality Therapy; Depressive Disorder, Major; Fema | 2006 |
Delusion of oral parasitosis in a patient with major depressive disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Delusions; Depressive Disorder, Major | 2006 |
Dramatic remission of treatment-resistant depression after the cessation of tricyclic antidepressants.
Topics: Adult; Antidepressive Agents, Tricyclic; Cabergoline; Depressive Disorder, Major; Dose-Response Rela | 2006 |
Serotonin, 5-HT1A serotonin receptors and proliferation of lymphocytes in major depression patients.
Topics: Adult; Antidepressive Agents, Tricyclic; Cell Proliferation; Concanavalin A; Depressive Disorder, Ma | 2007 |
Adequacy of continuation and maintenance treatments for major depression in Japan.
Topics: Adult; Antidepressive Agents, Tricyclic; Bipolar Disorder; Cohort Studies; Continuity of Patient Car | 2008 |
Treating schizophrenia with comorbid depressive or demoralization symptoms.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Fluphenazine; Humans; Imipramine; Morale; Prospect | 2008 |
[Imipramine and neuro-psychiatry. Retrospective study of 557 out-patients treated in a neuro-psychiatric unit (author's transl)].
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Aged; Bipolar Disorder; Depressive Disorder; Depr | 1982 |
[Treatment of involutional depression with maprotiline].
Topics: Aged; Anthracenes; Depressive Disorder, Major; Female; Humans; Imipramine; Male; Maprotiline; Middle | 1982 |
Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy.
Topics: Adult; Antidepressive Agents, Tricyclic; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cy | 1997 |
Nocturnal secretion of prolactin and cortisol and the sleep EEG in patients with major endogenous depression during an acute episode and after full remission.
Topics: Adult; Age Factors; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Cerebral Cortex; Circadia | 1997 |
Charles Bonnet syndrome with major depression in a Chinese middle-aged man.
Topics: Adult; Antidepressive Agents, Tricyclic; China; Cultural Characteristics; Delusions; Depressive Diso | 1997 |
Venlafaxine: new preparation. Just another antidepressant.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv | 1998 |
Serotonin-induced platelet intracellular Ca2+ responses in untreated depressed patients and imipramine responders in remission.
Topics: Adult; Antidepressive Agents, Tricyclic; Blood Platelets; Calcium; Depressive Disorder, Major; Femal | 1999 |
Platelet alpha2A-adrenoceptor function in major depression: Gi coupling, effects of imipramine and relationship to treatment outcome.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Tricyclic; Biomarkers; Blood Platelets; | 1999 |
Alpha-1-acid glycoprotein in major depressive disorder. Relationships to severity, response to treatment and imipramine plasma levels.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Biomarkers; Case-Control Studies; Depressive Di | 2000 |
Effects of antidepressant treatments on polymorphonuclear elastase levels in patients with depression.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Biomarkers; Depressive Disorder, Maj | 2000 |
Treatment of depression with associated anxiety: comparisons of tricyclic antidepressants and selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Clomipramine; Depressive Disorder, Major; Fluox | 2000 |
Treatment received by depressed patients in Japan and its determinants: naturalistic observation from a multi-center collaborative follow-up study.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cross-Cultural Comparison; Depressive Disorder, Majo | 2000 |
A comparison of two life stress assessment approaches: prospective prediction of treatment outcome in recurrent depression.
Topics: Adult; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Imipramine; Life Chang | 2000 |
Mood disorders in children and adolescents: psychopharmacological treatment.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Child; Depressive Disorder, Major; Drug Therapy, Combi | 2001 |
Treatment of mood-congruent psychotic depression with imipramine.
Topics: Adolescent; Adult; Affect; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Im | 2001 |
[Prediction of the effect of antidepressants in patients with endogenous depression].
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Depressive Disorder, Major; Fe | 1986 |
[On the clinical course and therapy of pathological conditions caused by incompatible antidepressants].
Topics: Adult; Anuria; Bipolar Disorder; Bis-Trimethylammonium Compounds; Depression; Depressive Disorder, M | 1968 |
The effects of antidepressant therapy. A follow-up study.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Drug Combinations; | 1971 |
[Influencing of biological and immunologic pregnancy reactions by psychotropic drugs].
Topics: Adolescent; Adult; Aged; Butyrophenones; Chlorpromazine; Dementia; Depressive Disorder, Major; Dysau | 1969 |
Persistent extrapyramidal oral dyskinesias following treatment with thymoleptics.
Topics: Aged; Amitriptyline; Antidepressive Agents; Depressive Disorder, Major; Facial Muscles; Female; Huma | 1970 |
Management of senile psychiatric disorders.
Topics: Adjustment Disorders; Affective Symptoms; Aged; Alcoholism; Amitriptyline; Dementia; Depressive Diso | 1968 |
Dreaming in the depressed.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Dreams; Female; Humans; Imipramine; | 1966 |
The metabolism of norepinephrine in depressions. Differences and effects of therapies.
Topics: Adult; Aged; Amitriptyline; Bipolar Disorder; Chlordiazepoxide; Chlorpromazine; Depression; Depressi | 1966 |
[Combined therapy in endogenous depression].
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Imipramine; Thioridazine | 1966 |